Gastro-intestinal disorders in Rett syndrome

Checklist for clinicians on assessment and management

Rett syndrome is a rare neuro-developmental disorder that occurs almost exclusively in females. The prevalence rate is approximately 1:5000 of the female population.

Rett syndrome is caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene which affects the nerves in the central nervous system. This affects many systems of the body:
- the nervous system (cognitive impairment, communication difficulties, and epilepsy)
- the respiratory system (hyperventilation and breath holding)
- the musculo-skeletal system (altered muscle tone, contractures, low bone density and scoliosis)
- the gastrointestinal system (gastro-oesophageal reflux, gastrointestinal dysmotility, abdominal distension, constipation and oromotor dysfunction). The multiple impacts of Rett syndrome have major health and lifestyle implications, both for the girls and women affected and for their family carers.

This leaflet is one of a series of publications developed by the Telethon Institute for Child Health Research in Western Australia to support better clinical assessment and management of health conditions commonly associated with Rett syndrome.

The content reflects issues cited by parent carers as important to them in responding to their daughter’s gastro-intestinal problems.

Other publications currently available in this series focus on clinical assessment and management of:
- scoliosis in Rett syndrome
- nutrition and growth in Rett syndrome.

A more comprehensive booklet on nutritional and digestive health in Rett syndrome has also been developed for families and carers and is available from rett.childhealthresearch.org.au

Many females with Rett syndrome experience gastro-intestinal problems that may inhibit the healthy enjoyment of food and/or limit nutritional intake. This brochure provides an overview of recommended practice in the clinical assessment and management of three of the most common gastro-intestinal problems associated with Rett syndrome:
- gastro-oesophageal reflux disease (GERD)
- constipation
- abdominal bloating.

REFLUX

Those with Rett syndrome are vulnerable to GERD, especially if motor function is poor. Reflux is also more likely if the person has scoliosis (commonly associated with Rett syndrome) or spends a lot of time in the supine position.

Assessment

The following signs may indicate gastro-oesophageal reflux:
- regurgitation, sour smelling burps or vomiting
- dental erosion
- unexplained weight loss
- iron deficiency anaemia
- food refusal and/or rumination
- recurrent lower respiratory tract infections
- behaviour problems (including agitation, self harm, screaming, restlessness for no apparent reason).

Investigations

Options to test for reflux include:
- 24 hr oesophageal pH monitoring (with preference for conducting a multiple channel intraluminal impedance study in combination with pH testing)
- upper GI endoscopy to assess whether there is reflux oesophagitis and/or gastritis
- radionuclide scintigraphy to test for aspiration due to reflux.

NOTE: A barium study may not be useful in the assessment of reflux.

DEVELOPING THIS CHECKLIST

These recommendations have been developed according to the process recommended by the National Health and Medical Research Council of Australia.

A staged method was employed:
- comprehensive literature search to identify relevant information
- consultation with parents and caregivers on their experiences of poor growth, calorie intake and feeding difficulties
- preparation of a draft set of recommendations
- appointment of an international and multidisciplinary panel of expert clinicians who reviewed successive drafts of the recommendations until agreement was reached.

Expert Panel

Members of the expert panel who reviewed the earlier drafts are listed below and we thank them for their contributions.

Sue Abraham PhD, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA;
Bruria Ben Zeev MD, Pediatric Neurology Institute, The Edmond & Lily Safra Children’s Hospital, Tel Hashomer, Israel;
Elana Bern MD MPH, Boston Children’s Hospital, Boston, Massachusetts, USA;
Sudha Budden MD, Pediatric Development and Rehabilitation, Legacy Emanuel Children’s Hospital, Portland, Oregon, USA;
Hilary Cass FRCPCH, Neurosciences Unit, Great Ormond Street Hospital for Children & Institute of Child Health, London, United Kingdom;
Carmelo Cuffari MD, The John Hopkins Hospital, Baltimore, Maryland, USA;
Carolyn Ellaway MBBS PhD FRACP CGHGSA, Western Sydney Genetics Program, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia;
John Fortunato Jr MD, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA;
Michael Freilinger MD, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria;
Suzanne Geerts RD MS, Civilian International Research Centre, University of Alabama, Birmingham, Alabama, USA;
Richard Haas MD, Department of Neurosciences, University of California San Diego, La Jolla, California, USA;
Peter Humphreys MD FRCP, Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada;
Mary Jones MD, Katie’s Clinic for Rett Syndrome, Children’s Hospital & Research Center, Oakland, California, USA;
Omar Khawaja MD PhD, Boston Children’s Hospital, Boston, Massachusetts, USA;
Jane Lane RN BSN, Civilian International Research Centre, University of Alabama, Birmingham, Alabama, USA;
Ted O’Loughlin FRACP, Department of Gastroenterology, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia;
Alan Percy MD, Department of Pediatrics and Neurology, University of Alabama, Birmingham, Alabama, USA;
Mercè Pineda MD PhD, Department of Neuropediatrics, Hospital Sant Joan de Déu, Barcelona, Spain;
Carolyn Schanen MD PhD, Human Genetics Research, A.I. du Pont Hospital for Children, Nemours Biomedical Research, Wilmington, Delaware, USA;
Catherine Senez BSc, Université Paris Diderot, Paris, France;
Steven Skinner MD, Greenwood Genetic Center, Greenwood, South Carolina, USA;
Eric Smeets MD PhD, Department of Clinical Genetics, Academic Hospital Maastricht, Maastricht, The Netherlands;
Sue Thompson BSc AdvAP, Genetic Metabolic Disorders Service, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia;
Batyra Weiss MD, Division of Pediatric Gastroenterology and Nutrition, The Edmond & Lily Safra Children’s Hospital, the Chaim Sheba Medical Center, Tel Hashomer, Israel;
Helena Wandin PhD student, Department of Public Health and Caring Sciences, Research in Disability and Rehabilitation, Uppsala University, Uppsala, Sweden;
Inggerd Witt-Engstrom MD PhD, Swedish Rett Center, Fosson, Sweden.

References

This checklist is based on the following:

Authors of checklist

Jenny Downs, BA(BSc) MSc PhD Helen Leonard, MBChB MPH Deidre Croft, BA DipCrim Madhur Ravikumar, MBBS MRCPCH FRACP Carolyn Ellaway, MBBS PhD FRACP CGHGSA Sue Thompson, BSc AdvAP Alan Percy, MD FAAN FAAP Gordon Baikie, MD FRACP

© The material in this document is copyright, the Telethon Institute for Child Health Research in Western Australia.
Management
A trial of conservative strategies is recommended before pharmacological and surgical strategies are considered.

Feeding, postural and behavioural strategies
Options may include:
• providing small, frequent feeds and/or thickened feeds
• creating a calm environment for eating (including the possibility of playing soothing music)
• eliminating selected foods from the diet commonly associated with GERD, and monitoring any impacts
• encouraging an upright position while eating (including the possibility of standing)
• elevating the head of the bed if the person is recumbent.

Pharmacological management of reflux
If more conservative management options are ineffective, pharmacological interventions may be trialled to supplement these strategies.

Proton pump inhibitors (PPIs, e.g. Lansoprazole, Omeprazole, Pantoprazole) are recommended as the drugs of choice.

It is recommended that PPIs initially be trialled once/day increasing to twice daily if symptoms of GERD persist.

Dosage should be maintained at the lowest level possible for effective symptom control.

PPIs can be used over the long term once they have been shown to be clinically effective. However, they may also be associated with diarrhoea, constipation or pain. If these side effects are experienced, an alternative PPI may be trialled, or the dosage of the existing drug reduced.

Other pharmacological options include:
• H2-blockers or H2-receptor antagonist reduce acid secretion but are less effectiveness than PPIs

Prokinetics should be used with extreme caution or avoided in girls with Rett syndrome because of their effect in prolonging QT interval. 20% of girls have a prolonged QT as part of Rett syndrome because of their effect in prolonging the QT interval.

A laparoscopic Nissen’s fundoplication is recommended if no contraindications exist as feeding goals are achieved more quickly and the duration of the hospital stay is shorter than with an open Nissen’s fundoplication.

The effectiveness of the fundoplication needs to be monitored carefully as symptoms may recur. Following a fundoplication girls and women with Rett syndrome may experience abdominal bloating, retching, dysphagia and/or dumping syndrome.

NOTE: There is no role for a prophylactic surgical anti-reflux therapy.

Surgical management of reflux
Surgical fundoplication is indicated if reflux is severe despite PPI therapy. Some treatment centres perform a fundoplication at the same time as a gastrostomy.

Nissen fundoplication has also been shown to improve weight gain in some children with Rett syndrome.

A laparoscopic Nissen’s fundoplication is recommended if no contraindications exist as feeding goals are achieved more quickly and the duration of the hospital stay is shorter than with an open Nissen’s fundoplication.

The effectiveness of the fundoplication needs to be monitored carefully as symptoms may recur. Following a fundoplication girls and women with Rett syndrome may experience abdominal bloating, retching, dysphagia and/or dumping syndrome.

NOTE: There is no role for a prophylactic surgical anti-reflux therapy.

CONSTANCE
Conspicuous is common in Rett syndrome. Females with Rett syndrome have limited communication skills and may not be able to express their discomfort due to constipation.

Assessment
Seek advice from the caregiver on the frequency and consistency of bowel actions.

Signs of constipation may include:
• grimming or crying with passage of stool
• decreased appetite
• irritability or behaviour changes

Testing for constipation
Physical examination of the abdomen is recommended. An x-ray of the abdomen is not required in a routine investigation for the diagnosis of constipation.

Management
Nutritional and behavioural strategies
Consistent use of strategies designed for each individual is helpful in preventing and managing constipation with particular attention to adequate intake of fluids and fibre, and maintaining mobility and physical activity.

Fluid intake
Fluid requirement for girls with Rett syndrome is generally the same as for the general population but is increased in the presence of hyperventilation and/or drooling. Ensuring adequate fluid intake is an important management strategy.

Fibre intake
Intake of fibre consistent with a healthy diet is recommended from wholegrain foods, fruit and vegetables.

Supplement the diet if necessary eg prune juice or soluble fibre eg Benefibre.

Physical activity
Inactivity can increase the likelihood of constipation. Maintaining mobility and/or physical activity is recommended in the management of constipation.

Toileting routine
Toilet timing to take advantage of the gastro-colic reflex should be encouraged. Where possible females should be encouraged to sit on the toilet within 30 minutes of meals.

Enteral feeding can also be supplemented with fibre.

Pharmacological management of constipation
If nutritional and behavioural strategies are not effective alone, pharmacological interventions should be used. The options below are listed in order of preference. More potent options are required if conservative approaches have been trialled and found to be ineffective. Consistent use is important once an effective dose has been found.

• Psyllium (Metamucil, Konsyl) or other high fibre preparations such as Benefibre can be used to increase the bulk of the stool (sufficient fluid intake is essential when psyllium or other high fibre preparations are used)
• Oral osmotic laxative treatments include Lactulose, Polyethylene glycol (Movicol or Miralax) and Milk of Magnesia and will soften the stool
• Lubricant laxatives include parefrin oil and Parachoc and coat the stool to make it pass more easily through the colon. Possible side effects relate to where there may be a risk of aspiration and oil in stools.
• Suppositories are indicated if dietary management and oral laxatives are inadequate
• An enema may be indicated if other strategies have proven ineffective.

NOTE: Soapsuds enemas and water enemas are not suitable, because of the risk of serious complications There is currently no evidence for the effectiveness of probiotics in the management of constipation.

Surgical management of constipation
If obstructive symptoms develop that are not responsive to medical treatment, manual disimpaction under general anaesthesia may be necessary.

ABDOMINAL BLOATING
Girls and women with Rett syndrome are prone to hyperventilation, breath holding and air swallowing that may contribute to abdominal bloating. Anxiety, pain and stress may exacerbate breathing dysfunction and abdominal bloating.

Assessment
Abdominal bloating may be indicated by:
• caregiver report of abdominal distension and pain
• history of change in abdominal girth
• lesser bloating on waking increasing during the day.

Investigations
Options include:
• observation of breath holding
• abdominal examination and palpation
• video fluoroscopy during feeding to monitor air swallowing.

NOTE: If bloating is associated with severe pain, tense abdomen and/or signs of shock, urgent medical assessment is required to exclude the rare complication of gastric perforation.

Management
Manage constipation as may exacerbate abdominal bloating. The action of simethicone in reducing the surface tension of gas bubbles may be effective in reducing abdominal bloating.

Where anxiety is associated with abdominal bloating, serotonin reuptake inhibitors may be considered. However, the potential risk of a prolonged QT interval should be taken into account before prescribing these drugs.

In cases of extremely severe abdominal bloating, a gastrostomy procedure may be considered. The gastrostomy can be used to release the build up of excess air.